Additional file 6 of MYCN and MAX alterations in Wilms tumor and identification of novel N-MYC interaction partners as biomarker candidates

Additional file 6: Table S1. Summary of mutation screening results and clinical data. Table S2. Overlap of WT patients with the MYCN P44L and DROSHA E1147K mutations. p = p-value (two-tailed Fisher's exact test). Table S3. Proteins identified in N-MYC protein complexes. Table S4. Cellular component clustering for N-MYC interacting proteins identified in MS. Table S5. Statistics of MYCN/YEATS2/PEG10 expression in Wilms tumor. Table S6. Oligonucleotides for MYCN and MAX mutation screening. Table S7. Oligonucleotides for gene cloning. Table S8. Doxycycline concentrations for MYCN/MAX induction. Table S9. Oligonucleotides for real-time PCR. Table S10. Antibodies for Western Blot.

附加文件6：表S1。突变筛查结果与临床资料汇总。表S2：野生型（Wild Type, WT）患者与MYCN P44L、DROSHA E1147K突变的重叠分布情况；注：p值为双侧Fisher精确检验所得的统计显著性p值。表S3：N-MYC蛋白复合物中鉴定获得的蛋白质。表S4：质谱（Mass Spectrometry, MS）鉴定得到的N-MYC互作蛋白质的细胞组分聚类分析结果。表S5：肾母细胞瘤中MYCN、YEATS2及PEG10的表达水平统计数据。表S6：用于MYCN与MAX突变筛查的寡核苷酸序列。表S7：用于基因克隆的寡核苷酸序列。表S8：用于MYCN/MAX诱导表达的多西环素浓度。表S9：用于实时荧光定量聚合酶链反应（Real-time PCR）的寡核苷酸序列。表S10：用于蛋白质印迹（Western Blot）的抗体。